The p53 gene was analyzed in tumor specimens obtained from 52 patients with various types of carcinoma of the thyroid gland by a combined molecular and immunocytochemical approach. The histologic types included 37 well-differentiated papillary and follicular carcinomas, 8 poorly differentiated, and 7 undifferentiated carcinomas. The p53 gene was shown to be unaffected in all differentiated tumors by single-strand conformation polymorphism analysis. However, in two out of eight (25%) of poorly differentiated carcinomas and five out of seven (71%) undifferentiated carcinomas, p53 mutations were identified and subsequently characterized by DNA sequencing. One undifferentiated carcinoma displayed two areas with varying degrees of differentiation. The comparative analysis of the p53 gene, in both the more and the less differentiated area of this tumor, clearly showed that the p53 mutation was confined to the latter component of the tumor specimen. These results indicate that mutations of the p53 gene are associated with the most aggressive histologic types of thyroid tumors, such as the undifferentiated carcinoma and, to a certain extent, the poorly differentiated carcinoma, and that the alterations of this gene represent a late genetic event in human thyroid carcinogenesis. (J. Clin. Invest. 1993Invest. .91:1753Invest. -1760.) Key words: immunocytochemistry * polymerase chain reaction * single-strand conformation polymorphismtumor progressiontumor suppressor gene Address reprint requests to Dr.
Introduction
In the last few years, increasing evidence has indicated a central role of the p53 tumor suppressor gene in human carcinogenesis. In fact, p53 allelic losses or mutations are frequent genetic alterations in human cancers of different tissue origin, including those of the colon, lung, breast, brain, and hemopoietic tissue ( 1, 2) .
The p53 mutations appear to be concentrated in a portion of the gene spanning exons 5-9, where the SV40 large-T binding domain and four evolutionary conserved regions map (3); a large variety of mutations has been observed in different codons covering these regions (1) . Furthermore, the available data indicate that the occurrence of p53 mutations can be re-garded either as an early or a late event in tumor progression depending on the tumor type (4) (5) (6) .
The tumors derived from the thyroid follicular epithelium comprise adenomas and carcinomas, the latter including the well-differentiated papillary and follicular types and the undifferentiated type. The well-differentiated carcinomas (WDCs)' are characterized by a low biological aggressiveness and an indolent course, whereas the undifferentiated carcinomas (UCs) display aggressive behavior with rapid fatal outcome (7, 8) . More recently, on the basis of several reports on differentiated carcinomas showing a more pronounced aggressiveness, the existence of a group of so-called poorly differentiated carcinomas (PDCs) with a prognosis intermediate between that of differentiated and undifferentiated subtypes was identified (9) (10) (11) (12) .
In spite oftheir common histogenic origin but in agreement with their different biologic and clinical features, the pathogenesis of the various histologic types appears to be associated with the occurrence of different genetic events. In fact, among differentiated carcinomas it has been determined that a frequent activation ofras oncogenes is present in all the stages ofprogression from follicular adenoma to follicular and UCs (13) (14) (15) , whereas in papillary thyroid carcinomas the two genes ret and Ntrkl (proto trk), whose products display all the features of a receptor tyrosine kinase, are activated in -50% of the analyzed cases (16) (17) (18) (19) (20) . In addition, two recent studies have investigated the role of p53 in thyroid tumors with contrasting results. Wright et al. (21 ) , in analyzing about 100 WDCs and 20 UCs found only one case of follicular carcinoma with p53 mutation. On the contrary, Ito et al. (22) , by analyzing 10 differentiated and 7 undifferentiated thyroid tumors, found p53 mutations in -85% of UCs.
To clarify this issue, we investigated for the presence ofp53 mutations a series of thyroid carcinomas both by molecular and immunocytochemical analysis. The results suggest that p53 mutations are restricted to the more aggressive histologic types and are associated with both dedifferentiation and progression.
Methods
Tumor storage and DNA extraction. Surgical specimens ofthyroid carcinomas were frozen in isopentane precooled by liquid nitrogen as well as formalin-fixed and paraffin-embedded. High molecular weight DNA extraction from normal and tumor samples was performed as previously reported ( 16) .
Single-strand conformation polymorphism (SSCP) analysis. Oligonucleotide primers for both the SSCP and DNA sequencing were described by Gaidano et al. (23) . The couples of primers were chosen in order to amplify the exons 5, 6, 7, 8, and 9. SSCP was accomplished according to an adapted version ofthe method described by Gaidano et al. (23) . The PCR reaction was performed with 100 ng of genomic DNA, 5 pmol of each primer, 2.5 MM each of dATP, dTTP, dGTP, 2.17 MM of dCTP, 5 ACi of [a-32P]dCTP (Amersham International, Amersham, UK; 3,000 Ci/mmol), 10 mM Tris HCl (pH 8.8), 50 mM KCl, MgCl2 1 mM (for exons 5, 6, 7, and 9) or 1.3 mM (for exon 8), 0.01% gelatin, 0.5 U of Taq DNA polymerase (Cetus-Perkin Elmer, Norwalk, CT) in a final volume of 5gl. The amplification, consisting in 30 cycles of denaturation (950C, 1 min), annealing (580C, 30 s for exon 8; 630C, 30 s for exons 5, 6, 7, and 9), and extension (720C, 1 min), was performed on an automated thermal cycler (Cetus-Perkin Elmer). The reaction mixture (5 Ml) was diluted 1:80 by adding 395 Ml of 0.1% SDS, 10 mM EDTA; 2 ,l of the dilution was then mixed with 18 Ml of sequencing stop solution (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol) containing 20 mM NaOH. Samples were heated at 95°C for 5 min, chilled on ice, and immediately loaded onto a 8% polyacrylamide-I X Tris-borate/EDTA (TBE) gel containing 10% glycerol (7% polyacrylamide/4% glycerol for the only exon 6). Gels were run at 8 W for 16-20 h at room temperature, fixed in 10% acetic acid, 10% methanol for 20 min, and then vacuum-dried. Autoradiography was performed at -80°C with intensifying screens for 4-72 h.
Sequencing. PCR products purified on gel were utilized as template in direct sequencing reactions. Sequencing was performed with [ a-35S ] dATP as label, using a Sequenase kit (United States Biochemical Corp., Cleveland, OH) according to the manufacturer's recommended protocols, or by reamplification with Taq polymerase and [5'-32P]-labeled primers as specified below.
2 pmol of the primer were 5' end-labeled by 5 U ofT4 polynucleotide kinase (New England Biolabs, Beverly, MA) in 5 Ml of a reaction mixture containing: 2 pmol of [y-32P]ATP (Amersham International; 5,000 Ci/mmol), 50 mM Tris HCl (pH 7.6), 10 mM MgCI2, 5 mM DTT, 0.1 mM spermidine, 0.1 mM EDTA (pH 8.0). The reaction mixture was incubated at 37°C for 30 min, then at 68°C for 10 min. For sequencing, purified amplified DNA was reamplified in the presence of one labeled primer, the four dNTPs, and one of the four ddNTPs (24) . The 18 cycles were executed with a denaturation step (95°C, 1 min ), an annealing step (58°C, 30 s for exon 8; 63°C, 30 s for exons 5, 6, 7, and 9), and an extension step (72°C, 2 min). Reactions were electrophoresed on 6% polyacrylamide/7.67 M urea/ lx TBE gel. When a tumor sample containing p53 mutation was identified, the result was confirmed by repeating the entire procedure: amplification of genomic DNA, fragment purification, and sequencing. To verify the tumor-associated nature of the observed p53 alterations, we analyzed by SSCP and/or by sequencing the homologous region ofthe p53 gene from the relative peripheral blood lymphocytes DNA of the cases displaying a mutated p53 in tumor sample.
Histology. In this study the term "poorly differentiated carcinoma" was used to classify differentiated carcinomas recently reported as carcinoma with intermediate malignancy, i.e., insular carcinoma (10), tall cell variant of papillary carcinoma ( 11), trabecular subtype ofpapillary carcinoma ( 12) , and PDC according to Sakamoto et al. (9) . UCs were classified according to World Health Organization criteria (25) .
Immunocytochemistry. Immunocytochemical staining of the p53 protein on frozen sections was carried out by the avidin-biotin complex technique with or without S-diaminobenzidine silver enhancement according to Frigo et al. (26) using the monoclonal antibody PAb24O at a dilution of 1:2,000 or 1:100, respectively. This antibody was raised against mutant forms of p53, but by immunocytochemistry it recognizes also the normal protein (27) . On paraffin-embedded sections, immunocytochemistry was performed using the polyclonal antiserum Two of these cases showed ras gene activation and two were negative for oncogenes activation. § Among these cases, three showed ras gene activation, two were negative for oncogenes activation, and three were not analyzed. 11 Among these cases, three were negative for oncogenes activation and four were not analyzed.
CM-1 raised against wild-type human p53 (Novocastra Laboratory, Newcastle, UK), but recognizing also the mutated protein, using a modification (28) of the method described by Shi et al. (29) . The two antibodies, irrespective of whether they were generated against mutated or wild-type p53, recognize a form of the protein whose half-life was increased by tumor-associated p53 gene alterations. They do not react with normal cells because of the physiologically short half-life of the p53 protein (2).
Results
SSCP analysis ofp53 gene. We examined by SSCP analysis a total of 52 DNA from 37 WDCs (33 papillary and 4 follicular), 8 PDCs, and 7 UCs. A previous analysis of 45 of these DNA by transfection assay and/or by molecular techniques revealed that 13 WDCs of the papillary type did not show an activation of dominant oncogenes, 13 were positive for ret, 6 for trkl transforming rearrangements, and 1 displayed a mutation of Nras, similarly, whereas two follicular carcinomas were negative, other two tumors of the same histotype showed Hras and Nras mutation, respectively (17, 18, 20 , and unpublished results). Among the PDCs and UCs, five were negative and in A ss sense three cases a mutation ofone ofeach member (N, H, and K) of the ras oncogene family was identified (Table I) .
The SSCP analysis revealed the occurrence of p53 gene alteration in four of the WDCs (data not shown). However, the subsequent sequence analysis of the affected exon showed that the mutated samples belonged to heterozygous individuals carrying a p53 allele with a silent mutation in exon 6 at codon 213, which defines a previously described constitutional genetic polymorphism (30, 31) . Therefore, this analysis shows that none ofthe WDCs analyzed, irrespective ofthe activation of a dominant oncogene, displayed a p53 gene alteration (Table I).
On the contrary, -50% of the 15 samples of PDCs and UCs, showed an alteration of one p53 exon (Table I) . The results of the SSCP analysis of six out of the seven mutated samples are shown in Fig. 1 . Two mutations mapped in exon S (Tl and T2), two in exon 6 (T3 and T4), two in exon 7 (T5 and T6), and one, not shown in the figure, in exon 8 (T7). In the majority ofthe mutated samples, the SSCP analysis showed the presence ofboth variant bands, corresponding to a mutated p53 allele, and ofbands related to the wild-type one. From case 6, an UC, three different specimens were available, two (D and U) representing different areas of the primary tumor (a more and a less differentiated area, respectively), and the third one relative to a lymph-nodal metastasis. As it can be seen in Fig. 1 , the more differentiated portion of the tumor (D) showed only the migration pattern of the wild-type exon 7, while both the less differentiated portion of the tumor (U) and the metastatic sample (M) displayed also a band with altered electrophoretic mobility, suggesting the presence of a mutated p53 allele. Nucleotide sequence analysis of p53 gene mutations. To characterize the p53 gene mutations detected by SSCP analysis, we determined the nucleotide sequence of the identified mutated samples by direct sequencing of the PCR-amplified exons. The results of our analysis, shown in Figs. 2, 3 , and 4 and summarized in Table II , revealed a peculiar pattern ofp53 alterations. In fact, whereas in the majority of the studies the most frequent p53 alteration reported was a point mutation (1), we found only two cases (T I and T7) with such an alteration. Fig. 2 shows the mutation (G --T) detected in sample T 1. Four other cases displayed a deletion of one or two bases (samples T2, T3, T4, and T5; Fig. 3 ) and another sample showed a dinucleotide duplication (sample T6; Fig. 4 ). Both the deletions and the duplication resulted in frameshift potentially coding for truncated forms ofthe p53 product (Table II) .
The reasons for this unusually high frequency of this kind of p53 gene alterations are not immediately evident.
In peripheral blood lymphocytes of all the patients whose tumors showed a mutated p53 gene, only the p53 wild-type sequence was detected. The lymphocytes of case T7 were not available. Fig. 3 B shows, in the antisense strand, that tumor N.3 contained also the silent mutation CGA/CGG at codon 213 that, as previously reported, we found also in four differentiated carcinomas and that was related to a constitutional genetic polymorphism.
Both SSCP and sequencing analyses revealed that in the majority ofthe samples the wild-type p53 sequence was clearly retained. At present, we cannot determine whether the normal allele resulted from a cellular heterogeneity of the samples (normal and tumor cells) as was apparent in case 5, or by a heterozygosity for the p53 mutations. Sequencing data from case 6, reported in Fig. 4 , confirmed the observations obtained by SSCP. In fact, whereas the samples from the undifferentiated portion of the primary tumor (Fig. 4, right panel) and the metastasis (data not shown) displayed the same p53 alteration (GT duplication at codon 240), the analysis ofthe DNA from the more differentiated area of the same tumor detected only wild-type p53 sequence (Fig. 4, left panel) .
Histology and immunocytochemical analysis. The case material consisted ofseven UCs and eight PDCs. Undifferentiated carcinomas included the following types: three spindle cell, three giant cell, and one small cell. In three of these tumors a residual well-differentiated component was present. PDCs were made up of the following types: three insular, three tall cell, one trabecular, and one poorly differentiated. Abbreviations: A, alive; DF, disease free; UN, unknown; WD, with disease; DOD, dead of disease. * Shorthand according to TNM system (Hermanek and Sobin [35] ).
Adrenal gland. § First surgical treatment elsewhere 6 (Ti 1), 3 (T14), and 2 (T15) mo before.
Laryngeal infiltration. 'PDC, poorly differentiated type (Sakamato et al. [9] ). ** UC, spindle-cell variant with residual differentiated component. t UC, giant-cell variant (T4 and T7) with residual differentiated portion (T6). " PDC, insular type.
On frozen sections, positive staining with PAb240 was observed on six out ofthe seven cases in which a molecular alteration ofp53 gene had been detected (Table III) . The reactivity covered the whole sample in two cases of UC (17 and T4) (an example is given in Fig. 5 ) and in one PDC (TI). In these samples > 80% of the nuclei were p53 positive. In the remaining positive cases, a selective distribution of nuclear immunostaining was detected in almost all tumoral cells belonging to sharply defined, less differentiated areas. Confirming the molecular findings, case T6 showed immunoreactivity restricted to the undifferentiated component of the tumor.
On paraffin-embedded samples, the CM-1 antiserum confirmed these results (Fig. 5) , and in two cases, T2 and T5, permanent sections showed better defined structural details compared to frozen sections. In the first case, a strong nuclear immunostaining was shown throughout the undifferentiated component only, whereas the surrounding more differentiated areas were either negative or displayed scattered foci of cells with weak nuclear reactivity (Fig. 6 ). In the second case, sharply defined areas of immunoreactivity were restricted to tumor tissue which showed a poorly differentiated pattern and evidence of aggressive growth, such as capsular invasion, neoplastic embolization within the tumor, and evidence ofinfiltration at the periphery (Fig. 7) .
As shown in Table III , the seven p53 positive tumors, including the one positive only by molecular analysis (T3), were stage pT4 and in two of them radical surgery could not be achieved. In addition, in four patients there were distant metastases at presentation and local progression at relapse in one patient.
Discussion
We analyzed for the presence of p53 gene mutations DNA samples from well-differentiated, poorly differentiated, and undifferentiated thyroid carcinomas. The results clearly indicate that p53 gene alterations do not represent a common genetic hallmark of thyroid carcinomas. In fact, none of the 37 WDCs analyzed showed abnormal electrophoretic behavior after SSCP analysis ofp53 exons 5-9. On the contrary, 7 out of the 15 PDCs and UCs were found to exhibit a mutated p53 gene by molecular and/or immunocytochemical techniques.
Ito et al. (22) recently reported similar results by direct sequencing of p53 exons 5-8 from 17 thyroid samples, including differentiated papillary adenocarcinomas and UCs. They did not find any p53 mutation in differentiated tumors, but six out of seven UCs were found to carry p53 mutations.
In contrast with these findings, Wright et al. (21) , who analyzed 129 thyroid tumor samples (including follicular adenomas, follicular and papillary carcinomas, and UCs) mainly by immunocytochemistry, detected the mutation of the p53 gene only in one differentiated thyroid carcinoma from which a continuous cell line was established. In contrast to colon, breast, and lung carcinomas, p53 alterations do not seem to play a significant role in thyroid carcinomas. Several factors could explain the discrepancy between these results and the above reported findings by Ito et al. (22) and our present analysis. Owing to the small number of cases analyzed in each report, it is not possible to exclude sampling bias. As already reported for other genetic alterations found in thyroid carcinomas such as ras mutations (15) and ret rearrangements ( 18) , the results might have been significantly affected by the different geographical origin ofthe tumors analyzed. Other differences in the experimental approach might also have contrib-
uted to these divergent results. In fact, all our cases of PDCs and UCs were analyzed by immunocytochemistry and by SSCP, and the affected exons were sequenced, whereas only 4 out ofthe 20 cases reported by Wright et al. (21 ) were analyzed in a similar way. In addition, these authors did not analyze p53 exon 6, where both we and Ito found some mutations.
Although it is generally accepted that a positive correlation exists between p53 abnormalities detected by molecular and immunocytochemical techniques, discrepancies between the two approaches may occur in both directions (32) . Also in our t,44 v' .1 \;
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In spite of this limitation our results clearly indicate that p53 alteration is associated with poorly differentiated and undifferentiated types of carcinoma of the thyroid gland and, most likely, with the progression ofthe tumor. In fact, in three cases where different stages of tumor evolution were recognizable, the comparison ofthe p53 immunostaining with the histological characteristics showed a selective distribution ofthe immunoreactivity to the more active growth fraction in PDCs and the anaplastic component in UCs. The area-to area heterogeneity linked to the close association between the intensity of the immunostaining and the morphological features ofdefinite aggressiveness and dedifferentiation within each ofthe two histologic types investigated suggests that alterations of p53 may be related to both the aquisition of invasive properties and loss of differentiation. Moreover, when the molecular analysis was performed separately on differentiated and undifferentiated areas ofthe same carcinoma, we found the p53 alterations to be associated only with the latter.
Altogether, these observations are in agreement with the previously suggested concept that both PDCs and UCs may derive from the progression of preexisting differentiated carci-
